Get in Touch

This site is intended for UK healthcare professionals only and contains promotional information.UK Flag Please visit the MHRA Yellowcard site to report an Adverse Event.

Home/Therapy areas/Diabetes and Endocrinology/Diabetes and Endocrinology Webinars and HCP Resources/Implementing SGLT2 inhibitor prescribing into your diabetes practice

Implementing SGLT2 Inhibitor Prescribing Into Your Diabetes Practice

Invokana®(canagliflozin) is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise:

  • As monotherapy when metformin is considered inappropriate due to intolerance or contraindications
  • In addition to other medicinal products for the treatment of diabetes

For study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, please refer to section 4.4, 4.5 and 5.1 of the Invokana SmPC. 

Prescribing Information can be found under Useful Resources

Implementing SGLT2 inhibitor prescribing into your diabetes practice- Alia Gilani

Senior Diabetes Clinical Pharmacist, Alia Gilani, explores the benefits of SGLT2 inhibitors in type 2 diabetes beyond glycaemic control, how to address clinical inertia and the clinical benefits of Invokana (canagliflozin) for type 2 diabetes.

This presentation was part of The Many Faces of Diabetes national webinar on the 14th of November 2023, titled “Primary Prevention in Primary Care.

Useful Resources

Alia Gilani- Senior Diabetes Clinical Pharmacist

Alia Gilani- Senior Diabetes Clinical Pharmacist

Alia is a Senior Diabetes Clinical Pharmacist whose interests lie in ethnic inequalities and diabetes. She helped established and run a bi-lingual medication review service in NHS Glasgow in 2002. This was the “MELT” service (Minority Ethnic Long Term medicines Service) which operated for an over a decade. The MELT was an open referral medication review service which allowed referrals to be received from both primary and secondary care. She has received several awards for her work in which the service has been recognised both locally and nationally. She has chaired the NHS Glasgow Diabetes Ethnicity and Inequalities Group in the past.

PP-IN-UK-1134 January 2024

Adverse events should be reported. Reporting forms and information can be found at www.yellowcard.mhra.gov.uk or search for MHRA Yellow Card in Google Play or Apple App Store.

Adverse events should also be reported to A. Menarini Farmaceutica Internazionale SRL.

Phone 0800 085 8678

Useful Links Edit Cookies Settings
Contact Us Get in Touch

This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc.

 

This website is brought to you by A. Menarini Farmaceutica Internazionale SRL, a company registered in England and Wales under No. BR016024 with its registered office at Menarini House, Mercury Park, Wycombe Lane, Wooburn Green, High Wycombe, HP10 0HH.

Copyright © 2021 Menarini. All rights reserved. VAT number 143099806. PP-MN-UK-0549 May 2024